Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc.
Your view on OTLK
Overview
What the company does, where it operates, and who runs it.
About Outlook Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robert Charles Jahr
- Headquarters
- Building F, Iselin, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Robert Charles Jahr
- Headquarters
- Building F, Iselin, NJ, US
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Outlook Therapeutics, Inc., and the rating behind it. OTLK last traded at $0.66; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Outlook Therapeutics, Inc.. Starting points for Outlook Therapeutics, Inc.: EPS -$2.40, beta 0.75 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Outlook Therapeutics, Inc.. Outlook Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Outlook Therapeutics, Inc.. Trailing twelve-month EPS for Outlook Therapeutics, Inc. stands at -$2.40. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Outlook Therapeutics, Inc.. Outlook Therapeutics, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Outlook Therapeutics, Inc. valued side by side against its closest peers. Outlook Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Outlook Therapeutics, Inc., and how their positions are changing. At a $123.4M market value, institutional positions materially move Outlook Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Outlook Therapeutics, Inc. executives and directors. Shares of Outlook Therapeutics, Inc. have traded between $0.79 and $5.44 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Outlook Therapeutics, Inc.. Outlook Therapeutics, Inc. is a $123.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Outlook Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Outlook Therapeutics, Inc.. Coverage tracks Outlook Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.